Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MedservRegisMAL:MDS 42 EBIT per Share is €0.12 as of Dec. 2025. GuruFocus rates MAL:MDS with a GF Score™ of 42/100 and a GF Value™ of €0.92 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 787 Oil & Gas companies, MedservRegis ranks worse than 127064.68% on this metric.
MedservRegis's EBIT per Share for the
six
months ended in Dec. 2025 was €0.06.
Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 was €0.12.
During the past 12 months, the average EBIT per Share Growth Rate of MedservRegis was 81.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for MedservRegis's EBIT per Share or its related term are showing as below:
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of MedservRegis was 54.90% per year. The lowest was -47.10% per year. And the median was 19.35% per year.
MAL:MDS's 3-Year EBIT Growth Rate is not ranked *
in the Oil & Gas industry.
Industry Median: -1.4 * Ranked among companies with meaningful 3-Year EBIT Growth Rate only.
MedservRegis's EBIT for the
six
months ended in Dec. 2025 was €5.6 Mil.
MedservRegis (MAL:MDS) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
MedservRegis EBIT per Share Related Terms
MedservRegis EBIT per Share Historical Data
* Premium members only.
The historical data trend for MedservRegis's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.12
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MedservRegis (MAL:MDS) has a EBIT per Share of €0.12 as of Dec. 2025. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on MedservRegis and its competitors. According to the industry distribution chart, MedservRegis ranks #999999 out of 787 companies in the Oil & Gas industry.
Is MedservRegis' EBIT per Share too high?
MedservRegis' current EBIT per Share is €0.12. Based on the distribution chart, MedservRegis ranks #999999 out of 787 companies in the Oil & Gas industry, which is in the bottom quartile relative to peers. Overall, MedservRegis has a GF Score™ of 42/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does MedservRegis' EBIT per Share compare to SLB and BKR?
According to the Oil & Gas industry distribution chart, MedservRegis ranks #999999 out of 787 companies for EBIT per Share. This places MedservRegis in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for an Oil & Gas company?
A good EBIT per Share depends on the Oil & Gas industry context. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on MedservRegis and its competitors. MedservRegis's current EBIT per Share is €0.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MedservRegis stock overvalued right now?
Based on GuruFocus' analysis, MedservRegis (MAL:MDS) is currently considered Modestly Undervalued. The stock's GF Value™ is €0.92, compared to a current price of €0.69 — trading 25% below its estimated fair value. The current EBIT per Share is €0.12. MedservRegis' overall GF Score™ is 42/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For MedservRegis (MAL:MDS), the current EBIT per Share is €0.12 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is MedservRegis (MAL:MDS) Overvalued in 2026?
Based on GuruFocus' analysis, MedservRegis stock appears to be undervalued.
The current stock price of €0.69 is trading 25% below its estimated GF Value™ of €0.92.
GuruFocus considers MedservRegis to be Modestly Undervalued.
Key valuation signals for MAL:MDS:
EBIT per Share: €0.12
GF Value™: €0.92 vs. price of €0.69 (25% below fair value)
No single metric tells the full story. See the MAL:MDS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
MedservRegis PLC is engaged in providing shore-based logistics to the offshore oil and gas industry and engineering and supply chain management for oil country tubular goods (OCTG) to support the onshore oil and gas industry. Its segment includes Integrated logistics support services; Oil country tubular goods; Trading activity and Photovoltaic farms. The company generates maximum revenue from the Integrated logistics support services segment, that Includes the provision of comprehensive logistical support services to the offshore oil and gas industry from the group's bases in Malta, Cyprus, Egypt, South America, and Africa.
42GF Score
Get the complete analysis for MAL:MDS
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MAL:MDS has been successfully added to your 
